uniQure (QURE) Expected to Announce Quarterly Earnings on Wednesday

uniQure (NASDAQ:QURE) will likely be issuing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.8223) per share and revenue of $5.4490 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Trading Down 1.2%

Shares of uniQure stock opened at $38.97 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $35.94 and a 200-day simple moving average of $25.66. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -11.20 and a beta of 0.90. uniQure has a 12-month low of $8.73 and a 12-month high of $71.50.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 164,429 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the completion of the transaction, the chief executive officer directly owned 558,810 shares of the company’s stock, valued at $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the sale, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 433,229 shares of company stock valued at $17,944,799. Insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. Smartleaf Asset Management LLC purchased a new stake in uniQure during the fourth quarter worth about $48,000. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure during the 3rd quarter valued at approximately $50,000. Ensign Peak Advisors Inc boosted its stake in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares in the last quarter. Knott David M Jr boosted its stake in shares of uniQure by 100.0% during the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,538 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on QURE. Chardan Capital boosted their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Mizuho lifted their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Finally, Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.